The researchers reviewed the cardiovascular risk among 41 362 men who had been treated with androgen deprivation therapy for prostate cancer. They then made a comparison of their cardiovascular outcomes with 187 785 age-matched, prostate cancer-free men on the same Swedish national healthcare register, using data on filled drug prescriptions.
展开▼
